Argenx cans Phase III Vyvgart Sjögren’s study on predicted efficacy fail

Phase 3negativeVyvgartVyvgart HytruloNegative

AI Analysis

Summary

Argenx has terminated its Phase III trial of Vyvgart in Sjögren's syndrome due to predicted efficacy failure. The company is pursuing further label expansion opportunities for Vyvgart Hytrulo in other immunological indications.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Not Met

Outcome Details

Phase III Vyvgart Sjögren's study discontinued due to predicted efficacy failure

Importance:7/10

Sentiment:

-0.80

Phase 3 failurestudy discontinuationSjögren's syndromeVyvgartlabel expansion

Related Companies

$ARGX

Read the original article

Published by Clinical Trials Arena on October 8, 2026 10:45 AM

Read Original